BACKGROUND: To evaluate the effect of liraglutide and NPH on blood glucose fluctuations in patients with newly diagnosed type 2 diabetes mellitus (T2DM). METHODS: A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group. They were treated for 12 weeks. The values of CGM, HbA1C, and BMI were measured and compared before and after treatment. RESULTS:FPG, HbAlc, and MBG were decreased in both groups after 12 weeks of treatment. In the liraglutide group, the MAGE, SDBG, LAGE, BMI, and waist circumference were significantly 1ower than in the NPH group (p<0.05). Patients in the liraglutide group had a greater incidence of gastrointestinal adverse effects than in the NPH group (p<0.05). The incidence of hypoglycemia episode in the liraglutide group was significantly lower than in the NPH group (p<0.05). CONCLUSIONS:Liraglutide achieved improvements in overall glycemic control similar to NPH in patients with newly diagnosed T2DM. Liraglutide was associated with less glucose fluctuation than NPH treatment as assessed by CGM. In addition, patients in the liraglutide group had a greater incidence of gastrointestinal adverse effects, a lower incidence of hypoglycemia, and some weight reduction.
RCT Entities:
BACKGROUND: To evaluate the effect of liraglutide and NPH on blood glucose fluctuations in patients with newly diagnosed type 2 diabetes mellitus (T2DM). METHODS: A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group. They were treated for 12 weeks. The values of CGM, HbA1C, and BMI were measured and compared before and after treatment. RESULTS: FPG, HbAlc, and MBG were decreased in both groups after 12 weeks of treatment. In the liraglutide group, the MAGE, SDBG, LAGE, BMI, and waist circumference were significantly 1ower than in the NPH group (p<0.05). Patients in the liraglutide group had a greater incidence of gastrointestinal adverse effects than in the NPH group (p<0.05). The incidence of hypoglycemia episode in the liraglutide group was significantly lower than in the NPH group (p<0.05). CONCLUSIONS: Liraglutide achieved improvements in overall glycemic control similar to NPH in patients with newly diagnosed T2DM. Liraglutide was associated with less glucose fluctuation than NPH treatment as assessed by CGM. In addition, patients in the liraglutide group had a greater incidence of gastrointestinal adverse effects, a lower incidence of hypoglycemia, and some weight reduction.
Authors: Oliver Schnell; Katharine Barnard; Richard Bergenstal; Emanuele Bosi; Satish Garg; Bruno Guerci; Thomas Haak; Irl B Hirsch; Linong Ji; Shashank R Joshi; Maarten Kamp; Lori Laffel; Chantal Mathieu; William H Polonsky; Frank Snoek; Philip Home Journal: Diabetes Technol Ther Date: 2017-05-22 Impact factor: 6.118
Authors: Juan P Frías; Samer Nakhle; James A Ruggles; Sergey Zhuplatov; Eric Klein; Rong Zhou; Poul Strange Journal: Diabetes Obes Metab Date: 2016-09-21 Impact factor: 6.577
Authors: Rosa Bretón-Romero; Robert M Weisbrod; Bihua Feng; Monika Holbrook; Darae Ko; Mary M Stathos; Ji-Yao Zhang; Jessica L Fetterman; Naomi M Hamburg Journal: J Am Heart Assoc Date: 2018-09-18 Impact factor: 5.501